作者:Jean-Dominique Bourzat、Marc Vuilhorgne、Laurent P. Rivory、Jacques Robert、Alain Commerçon
DOI:10.1016/0040-4039(96)01387-1
日期:1996.8
The semisynthesis of RPR 121056A (40, a major metabolite of irinotecan (CPT-11, 2), is reported starting from SN-38 (3) and an appropriate side-chain precusor, and using a 2-step sequence. This semisynthesis is based on the 10-O-acylation of SN-38 with the conveniently protected carbamoylchloride derivative 10 followed by cleavage of the benzylic protecting groups by hydrogenolysis. Preliminary in
RPR 121056A的(半合成4 0,伊立替康(CPT-11,的主要代谢物2),将报告从SN-38(起始3)和适当的侧链precusor,使用两步骤的序列。此半合成RPR 121056A是基于SN-38用方便保护的氨基甲酰氯衍生物10进行10-O-酰化,然后通过氢解裂解苄基保护基而得到的,体外初步结果表明RPR 121056A没有细胞毒性。